ATE505192T1 - Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein - Google Patents
Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- proteinInfo
- Publication number
- ATE505192T1 ATE505192T1 AT06772756T AT06772756T ATE505192T1 AT E505192 T1 ATE505192 T1 AT E505192T1 AT 06772756 T AT06772756 T AT 06772756T AT 06772756 T AT06772756 T AT 06772756T AT E505192 T1 ATE505192 T1 AT E505192T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- persons
- pharmaceutical composition
- kit protein
- mutant kit
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68911305P | 2005-06-09 | 2005-06-09 | |
| US73666805P | 2005-11-15 | 2005-11-15 | |
| US74841805P | 2005-12-08 | 2005-12-08 | |
| PCT/US2006/022564 WO2006135790A1 (en) | 2005-06-09 | 2006-06-09 | Methods of identifying and treating individuals exhibiting mutant kit protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE505192T1 true ATE505192T1 (de) | 2011-04-15 |
Family
ID=37027681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06772756T ATE505192T1 (de) | 2005-06-09 | 2006-06-09 | Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8247419B2 (de) |
| EP (1) | EP1909795B1 (de) |
| AT (1) | ATE505192T1 (de) |
| AU (1) | AU2006257919A1 (de) |
| CA (1) | CA2610157A1 (de) |
| DE (1) | DE602006021312D1 (de) |
| WO (1) | WO2006135790A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1904654A2 (de) * | 2005-07-15 | 2008-04-02 | Brystol-Myers Squibb Company | Verfahren zur identifizierung und zur behandlung von patienten, die mutierte src kinase polypeptide aufweisen |
| DE602006013826D1 (de) | 2005-07-20 | 2010-06-02 | Peter Valent | Zusammensetzungen zur behandlung von systemischer mastocytose |
| US20100286090A1 (en) * | 2005-11-14 | 2010-11-11 | Bristol-Myers Squibb Company | Treatment of Multiple Myeloma |
| US20100173426A1 (en) * | 2006-12-19 | 2010-07-08 | Johnson Faye M | Biomaker identifying the reactivation of stat3 after src inhibition |
| WO2008086342A2 (en) * | 2007-01-09 | 2008-07-17 | Bristol-Myers Squibb Company | Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells |
| EP2359813A1 (de) | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung mit N-(2-chlor-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolcarboxamid |
| CA2919498C (en) | 2013-07-31 | 2023-07-25 | Windward Pharma, Inc. | Aerosol nintedanib compounds and uses thereof |
| WO2015038190A1 (en) * | 2013-09-13 | 2015-03-19 | Life Technologies Corporation | Classification and actionability indices for cancer |
| IN2013MU03610A (de) | 2013-12-18 | 2015-04-24 | Dharmesh Mahendrabhai Shah | |
| CN105030776A (zh) * | 2015-06-24 | 2015-11-11 | 北京键凯科技有限公司 | Src蛋白抑制剂在制备预防和/治疗阿尔兹海默病药物中的应用 |
| AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11513887A (ja) * | 1995-10-27 | 1999-11-30 | ランバーグ，エリオット，アール． | 特定のヌクレオチド配列の検出方法および組成物 |
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6180408B1 (en) * | 1998-08-21 | 2001-01-30 | Washington University | Fluorescence polarization in nucleic acid analysis |
| JP2000080046A (ja) * | 1998-09-03 | 2000-03-21 | Dai Ichi Seiyaku Co Ltd | 多臓器障害の予防・治療剤 |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| EP1401429A2 (de) * | 2001-06-29 | 2004-03-31 | AB Science | Die verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von mastocysosis |
| US20040142888A1 (en) | 2002-08-07 | 2004-07-22 | Veeraswamy Manne | Modulators of RabGGT and methods of use thereof |
| JPWO2004080462A1 (ja) * | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | ｃ−Ｋｉｔキナーゼ阻害剤 |
| EP2003196A3 (de) * | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Krebs |
| US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| US20050215795A1 (en) * | 2004-02-06 | 2005-09-29 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| PT1885339E (pt) * | 2005-05-05 | 2015-10-12 | Bristol Myers Squibb Holdings Ireland | Formulações de um inibidor src/abl |
-
2006
- 2006-06-09 US US11/921,781 patent/US8247419B2/en active Active
- 2006-06-09 CA CA002610157A patent/CA2610157A1/en not_active Abandoned
- 2006-06-09 WO PCT/US2006/022564 patent/WO2006135790A1/en not_active Ceased
- 2006-06-09 DE DE602006021312T patent/DE602006021312D1/de active Active
- 2006-06-09 EP EP06772756A patent/EP1909795B1/de not_active Not-in-force
- 2006-06-09 AT AT06772756T patent/ATE505192T1/de not_active IP Right Cessation
- 2006-06-09 AU AU2006257919A patent/AU2006257919A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006135790A1 (en) | 2006-12-21 |
| EP1909795A1 (de) | 2008-04-16 |
| US8247419B2 (en) | 2012-08-21 |
| EP1909795B1 (de) | 2011-04-13 |
| US20090221601A1 (en) | 2009-09-03 |
| AU2006257919A1 (en) | 2006-12-21 |
| CA2610157A1 (en) | 2006-12-21 |
| DE602006021312D1 (de) | 2011-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
| DE602005020611D1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
| DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
| ATE551059T1 (de) | Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie | |
| ATE528302T1 (de) | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind | |
| DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| NO20075304L (no) | Metode for avtagende forkalkning | |
| ATE505192T1 (de) | Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein | |
| ATE459353T1 (de) | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen | |
| WO2005039486A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| IL185791A0 (en) | Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease | |
| ATE473728T1 (de) | Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare | |
| DE602004017332D1 (de) | Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| EP1961447A3 (de) | Behandlung depressiver Verstimmungen mit PKC-Aktivatoren | |
| DE602005015319D1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |